Altre lingue Spyre Therapeutics, Inc.

Azioni

SYRE

US00773J2024

Biotecnologia

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 09/12/2025			Variaz. 5gg	Var. 1 gen.
33,68 ^USD	-2,74%		+18,59%	+44,67%

06/11	SPYRE THERAPEUTICS, INC. : Deutsche Bank Securities ottimista sul caso	ZM
04/11	Spyre Therapeutics, Inc.: Risultati finanziari del terzo trimestre e dei primi nove mesi chiusi al 30 settembre 2025	CI

Altre lingue

Spyre Therapeutics Announces Grants of Inducement Awards	05/12
Spyre Therapeutics Announces Grants of Inducement Awards	07/11
Spyre Therapeutics : 20250930 EX 991 FINAL FINAL	04/11
Spyre Therapeutics: Q3 Earnings Snapshot	04/11
Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update	04/11
Spyre Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	04/11
Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody	04/11
Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended Anti-IL-23 Antibody	04/11
Spyre Therapeutics to Participate in Upcoming November Investor Conferences	29/10
Spyre Therapeutics to Participate in Upcoming November Investor Conferences	29/10
Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025	24/10
Spyre Therapeutics Closes $316.2 Million Public Offering	15/10
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million	15/10
Spyre Therapeutics Inc - Expects $486.2 million in cash and equivalents as of Sept 30, 2025 - SEC filing	14/10
Spyre Therapeutics Prices $275 Million Share Offering	14/10
Spyre Therapeutics announces pricing of $275 million public offering of common stock	14/10
Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock	14/10
Spyre Therapeutics Launches Public Offering	13/10
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants	13/10
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025	05/10
Spyre Therapeutics Announces Grants of Inducement Awards	03/10
Spyre Therapeutics, Inc. Doses First Patient in Pioneering Phase 2 SKYway Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases	15/09
Spyre doses first patient in phase 2 SKYWAY trial of SPY072, first anti-TL1A antibody for rheumatic diseases	15/09
Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases	15/09
Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases	15/09

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Trascrizioni Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Spyre Therapeutics, Inc.

Azioni

SYRE

US00773J2024

Biotecnologia

Altre lingue

Filtri